Matthew Wright

Investor Relations with @nwrcomms

[Underdog NBA @UnderdogNBA]

Officials for Monday's Spurs-Knicks Game 3:

Marc Davis
John Goble
Curtis Blair
Nick Buchert (alternate)

[ImmVirX @ImmVirX]

We're pleased to announce the presentation of new clinical and translational data for our lead candidate IVX037, alongside new preclinical data for our second program IVX055, at the AACR Annual Meeting 2026 in San Diego: https://t.co/E0QFZUf6ss

[Underdog NBA @UnderdogNBA]

Reed Sheppard in Saturday’s win:

23 PTS
14 AST (career-high)
4 STL
5 3PM
0 TO

First player in NBA history with that stat line.

[Nexalis Therapeutics Limited (ASX: NX1) @Nexalis_NX1]

We've been featured in @StockheadAU's Health Check, highlighting progress in our IRX-616a panic disorder program.

Read the full #NX1 article: https://t.co/82G32UvBBK

[Nexalis Therapeutics Limited (ASX: NX1) @Nexalis_NX1]

We’ve commenced the Phase 1 trial with the first eligible participant screened and recruited in the first-in-human study of IRX-616a.

The randomised, double-blind, placebo-controlled single ascending dose trial in healthy adult volunteers will define pharmacokinetics, safety and tolerability of IRX-616a, a differentiated delivery platform with inhaled CBD designed for rapid systemic absorption and fast onset.

The study is being conducted at CMAX, Adelaide, with independent Safety Review Committee oversight, informing future clinical development in acute anxiety-related indications.

Read the full #NX1 ASX Announcement here: https://t.co/kT83i3Wqnf

[ImmVirX @ImmVirX]

We're pleased to share that we have entered into a clinical supply agreement with BeOne Medicines AG to evaluate a combination therapy of our investigational oncolytic virus IVX055 with tislelizumab, BeOne’s PD-1 inhibitor: https://t.co/cZL7i59feR

[Syntara Limited @SyntaraTx]

Syntara has been named among Bioshares’ Top 6 Picks for 2026. The year ahead represents an unparalleled period for Syntara, with five clinical trials due to read out in 2026. Multiple independent programs are approaching value-defining data readouts, positioning the Company for a for a pivotal period in 2026.

$SNT #Syntara #Biotech

[Nexalis Therapeutics Limited (ASX: NX1) @Nexalis_NX1]

We’ve recently expanded our CNS-focused pipeline with SRX-25, an oral esketamine therapy targeting treatment-resistant depression (TRD), a condition that affects nearly one-third of patients with major depressive disorder.

Pharmaceutical ketamine is gaining traction worldwide as a rapid-acting intervention; however, existing treatment options have limitations in terms of drug delivery, given they are generally self-administered under supervision.

SRX-25 combines two well-known compounds (esketamine and a metabolic brake to increase the bioavailability) to overcome these challenges, aiming for at-home dosing, scalable delivery, and improved tolerability, positioning it as a next-generation option for TRD treatment.

SRX-25 joins our advancing programs IRX-211 (Breakthrough Cancer Pain) and IRX-616a (Panic Disorder) as we prepare to rebrand as Nexalis Therapeutics (ASX: NX1).

$IRX #MentalHealth #PharmaInnovation #CNS #Depression #Esketamine #KetamineTherapy #ASX #NX1 #InhaleRx

[Nexalis Therapeutics Limited (ASX: NX1) @Nexalis_NX1]

We’ve unveiled SRX-25, a first-in-class oral fixed-dose esketamine therapy that could transform care for treatment-resistant depression (TRD), one of the fastest-growing and most underserved markets in psychiatry.

SRX-25 pairs esketamine with a metabolic accelerator (CYP450 inhibitor) to boost bioavailability and deliver scalable, at-home dosing, positioning it as a clinical alternative to Spravato, without the burdens of in-clinic administration.

This strategic pivot puts InhaleRx at the centre of a US$4B TRD market, with a 505(b)(2) FDA regulatory pathway, a fully funded Phase 1/2 clinical program, and support from long-term partner Linlithgow Family Office.

We’re also proposing a rebrand to Nexalis Therapeutics (ASX: NX1) to reflect our broader focus as a CNS drug developer.

The pathway is capital-efficient. The unmet need is immense. The potential is transformative.

Read the full ASX Announcement here: https://t.co/KrJhUmuN5y

[Matthew Wright @mattwright3000]

'The Australian biotechs racing toward the next billion-dollar cancer drug'

The potential of CAR T therapies, and Australian players @TeamImugene, @WeAreArovella & @Chimeric, covered in @forbes_au today by Mark Whittaker.

https://t.co/XSbjsNoAoH

$IMU $ALA $CHM

[Stockhead @StockheadAU]

In a major commercial milestone, ReNerve has announced its flagship NervAlign nerve cuff has been approved for use across the US Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. #ASX $RNV https://t.co/f86pvrDlwm

[Neurotech International @NeurotechInt]

We’ve received Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett syndrome.

This milestone recognition complements the existing Orphan Drug Designation and strengthens our position in developing therapies for rare and underserved neurological disorders.

The designation provides access to FDA support, tax incentives, and up to seven years of market exclusivity if approved.

NTI164 is a unique anti-inflammatory and neuroprotective compound derived from a proprietary Cannabis sativa strain and is being evaluated in multiple clinical programs targeting neurodevelopmental disorders.

Read the full $NTI ASX Announcement here: https://t.co/W6wn7K6jfF

#Biotech #ASX #ASXnews #RettSyndrome #FDA

[Rubix Resources @RB6_ASX]

We have entered into a non-binding agreement with Nyos Metals & Yoro Metals to acquire a 100% interest in several exploration applications located in the Republic of Cameroon and the Republic of Congo: https://t.co/j4JkA58kw3 #RB6

[Imugene | Cancer Immunotherapies @TeamImugene]

We’re incredibly grateful to patient Brendan Roberts for bravely sharing his journey with lymphoma on 7NEWS Australia last night, as well as to journalist Amber Laidler and Associate Professor Matthew Ku from Royal Prince Alfred Hospital for highlighting the potential of our off-the-shelf CAR-T therapy, azer-cel.

The segment featured our CEO & MD, Leslie Chong and explored how azer-cel is delivering life-changing responses for patients who have exhausted conventional treatments. As Brendan said, “It would have been wonderful to have different options to consider.” This is exactly why we’re doing what we do.

📺 Watch the full story here: https://t.co/9BazJTpDon

$IMU #Immunotherapy #CAR_T #Lymphoma #CellTherapy #Biotech #AzerCel #CancerResearch #7NEWS #ClinicalTrials #ASX #CancerTreatment #BreakthroughTherapy @7NewsAustralia

[Syntara Limited @SyntaraTx]

Our CEO, Gary Phillips, presented in the "Finding the Next 10x" session at the 2025 Bioshares Biotech Summit in Hobart, outlining Syntara’s pipeline of first-in-class therapies for fibrotic diseases, including myelofibrosis and skin scarring.

Thank you to Bioshares for the opportunity to present.

#SNT #Syntara #Biotech #DrugDevelopment #Myelofibrosis #SkinScarring #FibroticDiseases #ClinicalTrials #Bioshares2025

[Chimeric Therapeutics ASX: CHM @Chimeric]

We’ve wrapped up at the 2025 Bioshares #Biotech Summit, where CEO Dr Rebecca McQualter presented in the “Finding the Next 10x” session, sharing progress on $CHM CDH17 and our clinical pipeline.

[Neurotech International @NeurotechInt]

Our Managing Director & CEO, Anthony Filippis joined today’s “Deal Making: The Real Story” panel at the 2025 Bioshares Biotech Summit, alongside fellow biotech leaders sharing real-world lessons on navigating transactions, partnerships, and growth.

Thanks to Bioshares for hosting an important conversation.

$NTI #BIO2025 #Bioshares2025 #Neurotech #ASX #NTI #Biotech #PaediatricNeurology #NTI164

[Nexalis Therapeutics Limited (ASX: NX1) @Nexalis_NX1]

“There’s a big gap in breakthrough cancer pain treatment… and IRX‑211 addresses that gap.”
Dr Sud Agarwal shares why IRX‑211 is gaining strong clinician support as we prepare for Phase 2 dosing.
Watch the full $IRX Town Hall: https://t.co/hgMVWmWNND

[Syntara Limited @SyntaraTx]

We've commenced initiation of AZALOX, a Phase 1b/2 multi-centre study evaluating amsulostat (SNT-5505) in combination with 5-Azacitidine for the treatment of high-risk Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML).

The study, supported by German Cancer Aid (Deutsche Krebshilfe), will be conducted at nine centres under Heidelberg University sponsorship.

Syntara CEO Gary Phillips stated: "We are delighted to be working with the German MDS Study Group as they initiate the AZALOX study. This represents an important milestone for amsulostat, leveraging the positive results in myelofibrosis and expanding to a second blood cancer indication. The AZALOX trial builds on promising preclinical data, potentially providing a new treatment option for patients suffering from MDS and CMML."

View the full announcement here: 2924-02968660-2A1609057&v=4a466cc3f899e00730cfbfcd5ab8940c41f474b6

[Imugene | Cancer Immunotherapies @TeamImugene]

📰 Media coverage by @Inside_PM

Take II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma Patients

Read the full article here: https://t.co/Xd7dE92EAH

#IMU #ASX #ASXNews